Mineralys Therapeutics Inc (MLYS)

$38.06 -2.40 (-5.93%)
Market Cap 2.68B
Revenue (ttm) 0.00
Net Income (ttm) -177.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 958,800
Avg Vol 1,754,578
Day's Range N/A - N/A
Shares Out 66.30M
Stochastic %K 20%
Beta 0.40
Analysts Strong Sell
Price Target $43.75

Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 378 6240
Address:
150 N. Radnor Chester Rd., Suite F200, Radnor, United States
Primeforrun
Primeforrun Oct. 3 at 6:09 PM
$MLYS discard
0 · Reply
Primeforrun
Primeforrun Oct. 3 at 5:59 PM
$MLYS sell??
1 · Reply
Smellmahass
Smellmahass Oct. 2 at 2:36 AM
$MLYS Missed opportunity. Seen this.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 1:50 AM
$MLYS: Unusual Options Activity Alerted PUT flow observed 200x contracts at Strike price of $35 Exp on 11/21/2025 with Premium of $27K and showing BULLISH Sentiment
0 · Reply
AskLou
AskLou Oct. 1 at 5:23 PM
$MLYS market pretty excited about them raising capital for trials. Shorts, might as well cover here before it hurts. https://grok.com/share/bGVnYWN5_f6d8fcdf-0242-419a-97e3-1007ef3782aa
0 · Reply
SocioCobb
SocioCobb Oct. 1 at 5:10 PM
$MLYS This form 4 from April!
0 · Reply
Doozio
Doozio Oct. 1 at 3:55 PM
$INOD to $GRRR s turning TTWO $MLYS and then $BILI ‘s during 🐒🍌🧠⏰♾️
0 · Reply
highnihilism
highnihilism Sep. 30 at 10:04 AM
$EWD iShares MSCI Sweden ETF: 28 trades, $43K vs $9K avg (4.71x !!!!). $43K calls / $0.4K puts. $NEWP New Pacific Metals: 115 trades, $43K vs $3K avg (14.45x !!!!). $42K calls / $0.5K puts. $MLYS Mineralys Therapeutics: 46 trades, $87K vs $77K avg (1.13x). $42K calls / $45K puts. $BBAR Banco Bbva Argentina: 122 trades, $90K vs $98K avg (0.92x). $42K calls / $48K puts.
0 · Reply
jitendermahajan
jitendermahajan Sep. 29 at 4:33 PM
$MLYS new here, what is the catalyst
1 · Reply
Doozio
Doozio Sep. 27 at 7:23 PM
The $MLYS are going to moar BILI’s like they have the QURE. 🐒🍌🧠⏰♾️
1 · Reply
Latest News on MLYS
Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions

Oct 1, 2025, 3:17 PM EDT - 3 days ago

Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Sep 30, 2025, 8:00 AM EDT - 4 days ago

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 15 days ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY SNDX TVTX

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Sep 5, 2025, 9:00 AM EDT - 4 weeks ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 4, 2025, 4:01 PM EDT - 4 weeks ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Sep 3, 2025, 8:17 AM EDT - 4 weeks ago

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BRKR

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Sep 2, 2025, 9:33 PM EDT - 4 weeks ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Sep 2, 2025, 4:01 PM EDT - 4 weeks ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 12:16 AM EDT - 7 weeks ago

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 7 weeks ago

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Aug 4, 2025, 4:05 PM EDT - 2 months ago

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Jun 30, 2025, 11:17 AM EDT - 3 months ago

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

Jun 17, 2025, 9:57 AM EDT - 3 months ago

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

May 24, 2025, 4:30 AM EDT - 4 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

May 20, 2025, 8:00 AM EDT - 4 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 8:20 PM EDT - 5 months ago

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:05 PM EDT - 5 months ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 7, 2025, 8:00 AM EDT - 5 months ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

May 5, 2025, 4:05 PM EDT - 5 months ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Apr 23, 2025, 5:23 PM EDT - 5 months ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mar 29, 2025, 2:30 PM EDT - 6 months ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 18, 2025, 4:01 PM EDT - 7 months ago

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mar 17, 2025, 8:00 AM EDT - 7 months ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Mar 12, 2025, 8:36 AM EDT - 7 months ago

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

LDI MOMO

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 11, 2025, 10:20 PM EDT - 7 months ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Mar 10, 2025, 6:25 PM EDT - 7 months ago

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Mar 10, 2025, 1:50 PM EDT - 7 months ago

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Mar 10, 2025, 1:09 PM EDT - 7 months ago

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:12 AM EDT - 7 months ago

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mar 10, 2025, 7:00 AM EDT - 7 months ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mar 7, 2025, 4:01 PM EST - 7 months ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 1:38 PM EST - 8 months ago

Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 12, 2025, 7:00 AM EST - 8 months ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Feb 5, 2025, 4:05 PM EST - 8 months ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Jan 19, 2025, 8:18 PM EST - 9 months ago

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 10:00 PM EST - 11 months ago

Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 4:05 PM EST - 11 months ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Nov 5, 2024, 4:05 PM EST - 11 months ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Nov 4, 2024, 4:05 PM EST - 11 months ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

The Schall Law Firm Invites Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 24, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 22, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 20, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud

Primeforrun
Primeforrun Oct. 3 at 6:09 PM
$MLYS discard
0 · Reply
Primeforrun
Primeforrun Oct. 3 at 5:59 PM
$MLYS sell??
1 · Reply
Smellmahass
Smellmahass Oct. 2 at 2:36 AM
$MLYS Missed opportunity. Seen this.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 1:50 AM
$MLYS: Unusual Options Activity Alerted PUT flow observed 200x contracts at Strike price of $35 Exp on 11/21/2025 with Premium of $27K and showing BULLISH Sentiment
0 · Reply
AskLou
AskLou Oct. 1 at 5:23 PM
$MLYS market pretty excited about them raising capital for trials. Shorts, might as well cover here before it hurts. https://grok.com/share/bGVnYWN5_f6d8fcdf-0242-419a-97e3-1007ef3782aa
0 · Reply
SocioCobb
SocioCobb Oct. 1 at 5:10 PM
$MLYS This form 4 from April!
0 · Reply
Doozio
Doozio Oct. 1 at 3:55 PM
$INOD to $GRRR s turning TTWO $MLYS and then $BILI ‘s during 🐒🍌🧠⏰♾️
0 · Reply
highnihilism
highnihilism Sep. 30 at 10:04 AM
$EWD iShares MSCI Sweden ETF: 28 trades, $43K vs $9K avg (4.71x !!!!). $43K calls / $0.4K puts. $NEWP New Pacific Metals: 115 trades, $43K vs $3K avg (14.45x !!!!). $42K calls / $0.5K puts. $MLYS Mineralys Therapeutics: 46 trades, $87K vs $77K avg (1.13x). $42K calls / $45K puts. $BBAR Banco Bbva Argentina: 122 trades, $90K vs $98K avg (0.92x). $42K calls / $48K puts.
0 · Reply
jitendermahajan
jitendermahajan Sep. 29 at 4:33 PM
$MLYS new here, what is the catalyst
1 · Reply
Doozio
Doozio Sep. 27 at 7:23 PM
The $MLYS are going to moar BILI’s like they have the QURE. 🐒🍌🧠⏰♾️
1 · Reply
Doozio
Doozio Sep. 27 at 5:47 PM
Wen da 🧠 flop lands yo go from $GRRR s TTWO $MLYS TTWO $BILI s. 🐒🍌🧠⏰♾️ https://youtube.com/shorts/x4Ymq8giy14?si=3uK99YrxIAf3LzEJ
0 · Reply
Doozio
Doozio Sep. 26 at 9:31 PM
$MLYS HTF as $XBI is now in $RYTM 🐒🍌🧠⏰♾️
0 · Reply
ericjamesharlow
ericjamesharlow Sep. 26 at 5:51 PM
$MLYS Bought December Puts, 35$ strike price. This Chart/RSI just doesn't look good.
0 · Reply
Defen
Defen Sep. 25 at 4:42 PM
$MLYS boy or boy did I f up on this one Owned 1000k at 12 amd sold 3 days later, and just got spooked out. Made 0
0 · Reply
RicoFDW
RicoFDW Sep. 19 at 9:08 AM
$MLYS painful to see it drops below $10 soon lol.
1 · Reply
Dale_Bridge
Dale_Bridge Sep. 19 at 8:34 AM
$MLYS This thing is lit, how much more? I'm more curious than interested, 25$ offering insiders and institutions own 95%+ float, tf is this doing in the market? No revenue, unprofitable, what drives this up?
2 · Reply
dripdipz
dripdipz Sep. 19 at 5:52 AM
$MLYS if opened below dont be scared. Diamond hands have insider new to $65+. LFGGG
0 · Reply
sallion5
sallion5 Sep. 19 at 1:54 AM
$MLYS $43 tomorrow
0 · Reply
highnihilism
highnihilism Sep. 16 at 6:40 PM
IWM: Russell 2000 → $IDR Idaho Strategic Resources $MLYS Mineralys Therapeutics $IE Ivanhoe Electric $LXU LSB Industries $MEG Montrose Environmental
0 · Reply
JarvisFlow
JarvisFlow Sep. 11 at 1:00 PM
Wells Fargo updates rating for Mineralys Therapeutics ( $MLYS ) to Overweight, target set at 26 → 50.
0 · Reply
SnoopDawg
SnoopDawg Sep. 10 at 12:23 PM
$MLYS sure would be nice to know what's going on lol. Better to be lucky than good I guess.
0 · Reply
jaypeezy99
jaypeezy99 Sep. 9 at 7:46 PM
$MLYS Someday someone will have to explain this one to me... Offering at 25.50... they should have waited until 40...
0 · Reply